{
    "clinical_study": {
        "@rank": "99097", 
        "arm_group": [
            {
                "arm_group_label": "OnabotulinumtoxinA Dose A", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA Dose A injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses."
            }, 
            {
                "arm_group_label": "OnabotulinumtoxinA Dose B", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA Dose B injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses."
            }, 
            {
                "arm_group_label": "OnabotulinumtoxinA Dose C", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA Dose C injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA for the\n      treatment of urinary incontinence due to neurogenic detrusor overactivity in patients who\n      successfully completed Study 191622-120."
        }, 
        "brief_title": "A Long-Term Extension Study of OnabotulinumtoxinA for Urinary Incontinence Due to Neurogenic Detrusor Overactivity", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Urinary Incontinence", 
        "condition_browse": {
            "mesh_term": "Urinary Incontinence"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Successfully completed participation in Study 191622-120\n\n          -  Aged \u2265 8 years to \u2264 17 years at the time of entry into Study 191622-120\n\n          -  Regularly using clean intermittent catheterization to empty the bladder\n\n        Exclusion Criteria:\n\n          -  Myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis\n\n          -  Current or planned use of a baclofen pump\n\n          -  Current or planned use of an electrostimulation/neuromodulation device for urinary\n             incontinence\n\n          -  Use of an indwelling catheter for urinary incontinence instead of using clean\n             intermittent catheterization to empty the bladder\n\n          -  Previous or current use of botulinum toxin therapy of any serotype for any urological\n             condition, or treatment with botulinum toxin of any serotype for any other condition\n             since entering study 191622-120"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "19 Years", 
            "minimum_age": "8 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01852058", 
            "org_study_id": "191622-121", 
            "secondary_id": "2012-004898-30"
        }, 
        "intervention": {
            "arm_group_label": [
                "OnabotulinumtoxinA Dose A", 
                "OnabotulinumtoxinA Dose B", 
                "OnabotulinumtoxinA Dose C"
            ], 
            "description": "OnabotulinumtoxinA injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.", 
            "intervention_name": "OnabotulinumtoxinA", 
            "intervention_type": "Biological", 
            "other_name": [
                "BOTOX\u00ae", 
                "botulinum toxin A"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 16, 2014", 
        "link": {
            "description": "More information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antwerpen", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kralove", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Czech Republic"
            ]
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Daily Average Frequency of Daytime Urinary Incontinence Episodes", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 60 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01852058"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Average Urine Volume at First Morning Catheterization", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 60 Weeks"
            }, 
            {
                "measure": "Percentage of Patients With Night Time Urinary Incontinence", 
                "safety_issue": "No", 
                "time_frame": "60 Weeks"
            }, 
            {
                "measure": "Time to Patient Request for Retreatment", 
                "safety_issue": "No", 
                "time_frame": "48 Weeks"
            }, 
            {
                "measure": "Time to Patient Qualification for Retreatment", 
                "safety_issue": "No", 
                "time_frame": "48 Weeks"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}